Skip to main content
Top
Published in: Calcified Tissue International 1/2018

01-01-2018 | Original Research

Kit W-sh Mutation Prevents Cancellous Bone Loss during Calcium Deprivation

Authors: Sutada Lotinun, Jaijam Suwanwela, Suchit Poolthong, Roland Baron

Published in: Calcified Tissue International | Issue 1/2018

Login to get access

Abstract

Calcium is essential for normal bone growth and development. Inadequate calcium intake increases the risk of osteoporosis and fractures. Kit ligand/c-Kit signaling plays an important role in regulating bone homeostasis. Mice with c-Kit mutations are osteopenic. The present study aimed to investigate whether impairment of or reduction in c-Kit signaling affects bone turnover during calcium deprivation. Three-week-old male WBB6F1/J-Kit W /Kit W-v /J (W/W v ) mice with c-Kit point mutation, Kit W-sh /HNihrJaeBsmJ (W sh /W sh ) mice with an inversion mutation in the regulatory elements upstream of the c-Kit promoter region, and their wild-type controls (WT) were fed either a normal (0.6% calcium) or a low calcium diet (0.02% calcium) for 3 weeks. μCT analysis indicated that both mutants fed normal calcium diet had significantly decreased cortical thickness and cancellous bone volume compared to WT. The low calcium diet resulted in a comparable reduction in cortical bone volume and cortical thickness in the W/W v and W sh /W sh mice, and their corresponding controls. As expected, the low calcium diet induced cancellous bone loss in the W/W v mice. In contrast, W sh /W sh cancellous bone did not respond to this diet. This c-Kit mutation prevented cancellous bone loss by antagonizing the low calcium diet-induced increase in osteoblast and osteoclast numbers in the W sh /W sh mice. Gene expression profiling showed that calcium deficiency increased Osx, Ocn, Alp, type I collagen, c-Fms, M-CSF, and RANKL/OPG mRNA expression in controls; however, the W sh mutation suppressed these effects. Our findings indicate that although calcium restriction increased bone turnover, leading to osteopenia, the decreased c-Kit expression levels in the W sh /W sh mice prevented the low calcium diet-induced increase in cancellous bone turnover and bone loss but not the cortical bone loss.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A (1988) The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335(6185):88–89. doi:10.1038/335088a0 CrossRefPubMed Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A (1988) The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335(6185):88–89. doi:10.​1038/​335088a0 CrossRefPubMed
2.
go back to reference Geissler EN, Ryan MA, Housman DE (1988) The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55(1):185–192CrossRefPubMed Geissler EN, Ryan MA, Housman DE (1988) The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55(1):185–192CrossRefPubMed
3.
go back to reference Tajima Y, Huang EJ, Vosseller K, Ono M, Moore MA, Besmer P (1998) Role of dimerization of the membrane-associated growth factor kit ligand in juxtacrine signaling: the Sl17H mutation affects dimerization and stability-phenotypes in hematopoiesis. J Exp Med 187(9):1451–1461CrossRefPubMedPubMedCentral Tajima Y, Huang EJ, Vosseller K, Ono M, Moore MA, Besmer P (1998) Role of dimerization of the membrane-associated growth factor kit ligand in juxtacrine signaling: the Sl17H mutation affects dimerization and stability-phenotypes in hematopoiesis. J Exp Med 187(9):1451–1461CrossRefPubMedPubMedCentral
8.
go back to reference El Hajj Dib I, Gallet M, Mentaverri R, Sevenet N, Brazier M, Kamel S (2006) Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 551(1–3):27–33. doi:10.1016/j.ejphar.2006.09.007 El Hajj Dib I, Gallet M, Mentaverri R, Sevenet N, Brazier M, Kamel S (2006) Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 551(1–3):27–33. doi:10.​1016/​j.​ejphar.​2006.​09.​007
9.
go back to reference Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H (2006) Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 24(4):274–282. doi:10.1007/s00774-006-0684-1 CrossRefPubMed Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, Yoshikawa H (2006) Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 24(4):274–282. doi:10.​1007/​s00774-006-0684-1 CrossRefPubMed
10.
go back to reference O’Sullivan S, Horne A, Wattie D, Porteous F, Callon K, Gamble G, Ebeling P, Browett P, Grey A (2009) Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 94(4):1131–1136. doi:10.1210/jc.2008-2324 CrossRefPubMed O’Sullivan S, Horne A, Wattie D, Porteous F, Callon K, Gamble G, Ebeling P, Browett P, Grey A (2009) Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 94(4):1131–1136. doi:10.​1210/​jc.​2008-2324 CrossRefPubMed
12.
go back to reference O’Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, Watson M, Cornish J, Browett P, Grey A (2007) Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 22(11):1679–1689. doi:10.1359/jbmr.070719 CrossRefPubMed O’Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, Watson M, Cornish J, Browett P, Grey A (2007) Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 22(11):1679–1689. doi:10.​1359/​jbmr.​070719 CrossRefPubMed
14.
go back to reference Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino AC (2013) Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. J Clin Endocrinol Metab 98(1):67–76. doi:10.1210/jc.2012-2426 CrossRefPubMed Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino AC (2013) Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. J Clin Endocrinol Metab 98(1):67–76. doi:10.​1210/​jc.​2012-2426 CrossRefPubMed
15.
go back to reference Aleman JO, Farooki A, Girotra M (2014) Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr Relat Cancer 21(3):R247–R259. doi:10.1530/ERC-12-0400 CrossRefPubMed Aleman JO, Farooki A, Girotra M (2014) Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr Relat Cancer 21(3):R247–R259. doi:10.​1530/​ERC-12-0400 CrossRefPubMed
16.
go back to reference Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468–1486. doi:10.1002/jbmr.141 CrossRefPubMed Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468–1486. doi:10.​1002/​jbmr.​141 CrossRefPubMed
17.
go back to reference Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(1):2–17. doi:10.1002/jbmr.1805 CrossRefPubMedPubMedCentral Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(1):2–17. doi:10.​1002/​jbmr.​1805 CrossRefPubMedPubMedCentral
20.
go back to reference Behrends DA, Cheng L, Sullivan MB, Wang MH, Roby GB, Zayed N, Gao C, Henderson JE, Martineau PA (2014) Defective bone repair in mast cell deficient mice with c-Kit loss of function. Eur cells Mater 28:209–221 discussion 221-202 CrossRef Behrends DA, Cheng L, Sullivan MB, Wang MH, Roby GB, Zayed N, Gao C, Henderson JE, Martineau PA (2014) Defective bone repair in mast cell deficient mice with c-Kit loss of function. Eur cells Mater 28:209–221 discussion 221-202 CrossRef
22.
go back to reference Choeyprasert W, Yansomdet T, Natesirinilkul R, Wejaphikul K, Charoenkwan P (2017) Adverse effects of imatinib in children with chronic myelogenous leukemia. Pediatr Int 59(3):286–292. doi:10.1111/ped.13136 CrossRefPubMed Choeyprasert W, Yansomdet T, Natesirinilkul R, Wejaphikul K, Charoenkwan P (2017) Adverse effects of imatinib in children with chronic myelogenous leukemia. Pediatr Int 59(3):286–292. doi:10.​1111/​ped.​13136 CrossRefPubMed
23.
go back to reference Berman E, Girotra M, Cheng C, Chanel S, Maki R, Shelat M, Strauss HW, Fleisher M, Heller G, Farooki A (2013) Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res 37(7):790–794. doi:10.1016/j.leukres.2013.02.005 CrossRefPubMed Berman E, Girotra M, Cheng C, Chanel S, Maki R, Shelat M, Strauss HW, Fleisher M, Heller G, Farooki A (2013) Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res 37(7):790–794. doi:10.​1016/​j.​leukres.​2013.​02.​005 CrossRefPubMed
25.
go back to reference Narayanan KR, Bansal D, Walia R, Sachdeva N, Bhansali A, Varma N, Marwaha RK (2013) Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer 60(7):1148–1153. doi:10.1002/pbc.24397 CrossRefPubMed Narayanan KR, Bansal D, Walia R, Sachdeva N, Bhansali A, Varma N, Marwaha RK (2013) Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer 60(7):1148–1153. doi:10.​1002/​pbc.​24397 CrossRefPubMed
26.
go back to reference Ceponis A, Konttinen YT, Takagi M, Xu JW, Sorsa T, Matucci-Cerinic M, Santavirta S, Bankl HC, Valent P (1998) Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol 25(12):2304–2314PubMed Ceponis A, Konttinen YT, Takagi M, Xu JW, Sorsa T, Matucci-Cerinic M, Santavirta S, Bankl HC, Valent P (1998) Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol 25(12):2304–2314PubMed
27.
go back to reference Ble C, Tsitsopoulos PP, Anestis DM, Hadjileontiadou S, Koletsa T, Papaioannou M, Tsonidis C (2016) Osteoporotic spinal burst fracture in a young adult as first presentation of systemic mastocytosis. J Surg Case Rep. doi:10.1093/jscr/rjw063 PubMedPubMedCentral Ble C, Tsitsopoulos PP, Anestis DM, Hadjileontiadou S, Koletsa T, Papaioannou M, Tsonidis C (2016) Osteoporotic spinal burst fracture in a young adult as first presentation of systemic mastocytosis. J Surg Case Rep. doi:10.​1093/​jscr/​rjw063 PubMedPubMedCentral
28.
go back to reference Benucci M, Bettazzi C, Bracci S, Fabiani P, Monsacchi L, Cappelletti C, Manfredi M, Ciolli S (2009) Systemic mastocytosis with skeletal involvement: a case report and review of the literature. Clin Cases Miner Bone Metab 6(1):66–70PubMedPubMedCentral Benucci M, Bettazzi C, Bracci S, Fabiani P, Monsacchi L, Cappelletti C, Manfredi M, Ciolli S (2009) Systemic mastocytosis with skeletal involvement: a case report and review of the literature. Clin Cases Miner Bone Metab 6(1):66–70PubMedPubMedCentral
29.
go back to reference Jonsson S, Standal T, Olsson B, Mellstrom D, Wadenvik H (2012) Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib. Am J Hematol 87(5):550–552. doi:10.1002/ajh.23155 CrossRefPubMed Jonsson S, Standal T, Olsson B, Mellstrom D, Wadenvik H (2012) Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib. Am J Hematol 87(5):550–552. doi:10.​1002/​ajh.​23155 CrossRefPubMed
30.
go back to reference Duttlinger R, Manova K, Chu TY, Gyssler C, Zelenetz AD, Bachvarova RF, Besmer P (1993) W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development 118(3):705–717PubMed Duttlinger R, Manova K, Chu TY, Gyssler C, Zelenetz AD, Bachvarova RF, Besmer P (1993) W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development 118(3):705–717PubMed
31.
go back to reference Stauffer M, Baylink D, Wergedal J, Rich C (1973) Decreased bone formation, mineralization, and enhanced resorption in calcium-deficient rats. Am J Physiol 225(2):269–276PubMed Stauffer M, Baylink D, Wergedal J, Rich C (1973) Decreased bone formation, mineralization, and enhanced resorption in calcium-deficient rats. Am J Physiol 225(2):269–276PubMed
33.
go back to reference Antic VN, Fleisch H, Muhlbauer RC (1996) Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet. Calcif Tissue Int 58(6):443–448CrossRefPubMed Antic VN, Fleisch H, Muhlbauer RC (1996) Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet. Calcif Tissue Int 58(6):443–448CrossRefPubMed
34.
go back to reference Tanimoto H, Lau KH, Nishimoto SK, Wergedal JE, Baylink DJ (1991) Evaluation of the usefulness of serum phosphatases and osteocalcin as serum markers in a calcium depletion-repletion rat model. Calcif Tissue Int 48(2):101–110CrossRefPubMed Tanimoto H, Lau KH, Nishimoto SK, Wergedal JE, Baylink DJ (1991) Evaluation of the usefulness of serum phosphatases and osteocalcin as serum markers in a calcium depletion-repletion rat model. Calcif Tissue Int 48(2):101–110CrossRefPubMed
35.
go back to reference Akesson K, Lau KH, Johnston P, Imperio E, Baylink DJ (1998) Effects of short-term calcium depletion and repletion on biochemical markers of bone turnover in young adult women. J Clin Endocrinol Metab 83(6):1921–1927. doi:10.1210/jcem.83.6.4891 PubMed Akesson K, Lau KH, Johnston P, Imperio E, Baylink DJ (1998) Effects of short-term calcium depletion and repletion on biochemical markers of bone turnover in young adult women. J Clin Endocrinol Metab 83(6):1921–1927. doi:10.​1210/​jcem.​83.​6.​4891 PubMed
36.
go back to reference Iwamoto J, Takeda T, Sato Y, Yeh JK (2004) Response of cortical and cancellous bones to mild calcium deficiency in young growing female rats: a bone histomorphometry study. Exp Anim 53(4):347–354CrossRefPubMed Iwamoto J, Takeda T, Sato Y, Yeh JK (2004) Response of cortical and cancellous bones to mild calcium deficiency in young growing female rats: a bone histomorphometry study. Exp Anim 53(4):347–354CrossRefPubMed
37.
go back to reference Lowe NM, Ellahi B, Bano Q, Bangash SA, Mitra SR, Zaman M (2011) Dietary calcium intake, vitamin D status, and bone health in postmenopausal women in rural Pakistan. J Health, Popul Nutr 29(5):465–470CrossRef Lowe NM, Ellahi B, Bano Q, Bangash SA, Mitra SR, Zaman M (2011) Dietary calcium intake, vitamin D status, and bone health in postmenopausal women in rural Pakistan. J Health, Popul Nutr 29(5):465–470CrossRef
38.
go back to reference Thomas GP, Baker SU, Eisman JA, Gardiner EM (2001) Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol 170(2):451–460CrossRefPubMed Thomas GP, Baker SU, Eisman JA, Gardiner EM (2001) Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol 170(2):451–460CrossRefPubMed
Metadata
Title
Kit W-sh Mutation Prevents Cancellous Bone Loss during Calcium Deprivation
Authors
Sutada Lotinun
Jaijam Suwanwela
Suchit Poolthong
Roland Baron
Publication date
01-01-2018
Publisher
Springer US
Published in
Calcified Tissue International / Issue 1/2018
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-017-0334-8

Other articles of this Issue 1/2018

Calcified Tissue International 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.